Abstract
Background and Aims: Factor Xa (FXa) and thrombin are coagulation serine proteases, which also exert non-haemostatic effects on various cell types through protease-activated receptors. Dabigatran and rivaroxaban are direct oral anticoagulants (DOACs) that inhibit thrombin’s and FXa’s action, respectively, and are used in clinical practice. We investigated the effect of dabigatran and rivaroxaban on FXa- and thrombin- induced platelet aggregation, in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
